ANTELOPE

  • Research type

    Research Study

  • Full title

    ANTELOPE: AsessmeNT of bonE LOss in men receiving treatment for ProstatE cancer

  • IRAS ID

    206171

  • Contact name

    Janet Brown

  • Contact email

    j.e.brown@sheffield.ac.uk

  • Sponsor organisation

    Sheffield Teaching Hospitals R&D

  • Clinicaltrials.gov Identifier

    NCT02785627

  • Duration of Study in the UK

    3 years, 0 months, 5 days

  • Research summary

    Prostate cancer is the commonest non-skin cancer in men, with over 40,000 new cases diagnosed in the UK each year. Development of prostate cancer depends upon testosterone (the male hormone) and medications that block testosterone can help men to survive for many years.

    However, blocking testosterone causes bone loss which may lead to osteoporosis (weak bones, likely to fracture). Fractures cause pain, loss of mobility and independence. One in three men will die within one year of a hip fracture. The osteoporosis caused by prostate cancer treatments differs from most other forms, because it affects the wrist more than other bones (eg spine/hip). If we can understand how prostate cancer treatments affect bones, this will help in the choice of the best prostate cancer treatment and which osteoporosis medication will best protect these men against broken bones.

    In this study, we will assess the bone health of two groups of men with prostate cancer receiving different treatments. We will compare these groups with a third group of healthy men who do not have prostate cancer. The men will have scans and blood tests at the start of their treatment and after one year to see how their bones change.

    Participants will attend a research site within Sheffield Teaching Hospitals for assessments, including the Northern General Hospital.

    Visit 1 (Baseline)
    Informed consent
    Fasted blood sample
    Questionnaire completion
    Height and weight measurements
    Grip strength, sit-stand test and six-metre walk test
    In two groups, three bone scans will be carried out
    1) A DXA scan
    2) An Xtreme CT scan of the forearm
    3) A CT scan of the T12 vertebra (spine)
    In a third group, only the DXA scan and Xtreme CT scan will be carried out.

    Visit 2 (12 months)
    Baseline assessments will be repeated.

    The study is funded by the Weston Park Hospital Charity.

  • REC name

    Yorkshire & The Humber - South Yorkshire Research Ethics Committee

  • REC reference

    16/YH/0335

  • Date of REC Opinion

    4 Oct 2016

  • REC opinion

    Further Information Favourable Opinion